n(g),n(g')-dimethyl-l-arginine has been researched along with Ventricular Dysfunction, Left in 15 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Elevated plasma levels of asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase (eNOS) inhibitor, may contribute to endothelial dysfunction in chronic heart failure (CHF)." | 9.13 | Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. ( Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM, 2008) |
| "This prospective study investigated whether plasma asymmetric dimethylarginine (ADMA) concentrations are related to cardiovascular events in patients with acute heart failure." | 7.74 | Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. ( Altenberger, J; Dückelmann, C; Haider, DG; Mittermayer, F; Wolzt, M, 2008) |
| "Asymmetric dimethylarginine plasma levels were significantly higher in pts with appropriate ICD intervention compared with those without any ICD intervention (0." | 5.37 | Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction. ( Bode-Böger, SM; Bukowska, A; Ghanem, A; Goette, A; Hammwöhner, M; Klein, HU; Lehmann, HI; Martens-Lobenhoffer, J; Röhl, FW, 2011) |
| "Elevated plasma levels of asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase (eNOS) inhibitor, may contribute to endothelial dysfunction in chronic heart failure (CHF)." | 5.13 | Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. ( Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM, 2008) |
| " In contrast, cDDAH1 KO mice exposed to TAC showed no increase in LV DDAH1 expression, slightly increased LV tissue ADMA levels, no increase in plasma ADMA, but significantly exacerbated LV hypertrophy, fibrosis, nitrotyrosine production, and LV dysfunction." | 3.85 | Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction. ( Atzler, D; Böger, RH; Chen, P; Chen, Y; Fassett, J; Guo, H; Hu, X; Kwak, D; Liu, X; Lu, Z; Schwedhelm, E; Wang, H; Xu, X; Yue, W; Zhang, P, 2017) |
| "This prospective study investigated whether plasma asymmetric dimethylarginine (ADMA) concentrations are related to cardiovascular events in patients with acute heart failure." | 3.74 | Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. ( Altenberger, J; Dückelmann, C; Haider, DG; Mittermayer, F; Wolzt, M, 2008) |
| "Asymmetric dimethylarginine plasma levels were significantly higher in pts with appropriate ICD intervention compared with those without any ICD intervention (0." | 1.37 | Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction. ( Bode-Böger, SM; Bukowska, A; Ghanem, A; Goette, A; Hammwöhner, M; Klein, HU; Lehmann, HI; Martens-Lobenhoffer, J; Röhl, FW, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Leffler, KE | 1 |
| Abdel-Rahman, AA | 1 |
| Burger, AL | 1 |
| Stojkovic, S | 1 |
| Diedrich, A | 1 |
| Demyanets, S | 1 |
| Wojta, J | 1 |
| Pezawas, T | 1 |
| Xu, X | 1 |
| Zhang, P | 1 |
| Kwak, D | 1 |
| Fassett, J | 1 |
| Yue, W | 1 |
| Atzler, D | 1 |
| Hu, X | 1 |
| Liu, X | 1 |
| Wang, H | 1 |
| Lu, Z | 1 |
| Guo, H | 1 |
| Schwedhelm, E | 2 |
| Böger, RH | 2 |
| Chen, P | 1 |
| Chen, Y | 1 |
| Pang, P | 1 |
| Abbott, M | 1 |
| Abdi, M | 1 |
| Fucci, QA | 1 |
| Chauhan, N | 1 |
| Mistri, M | 1 |
| Proctor, B | 1 |
| Chin, M | 1 |
| Wang, B | 1 |
| Yin, W | 1 |
| Lu, TS | 1 |
| Halim, A | 1 |
| Lim, K | 1 |
| Handy, DE | 1 |
| Loscalzo, J | 1 |
| Siedlecki, AM | 1 |
| El Shahawy, Y | 1 |
| Soliman, Y | 1 |
| Rifaie, A | 1 |
| Shenawy, H | 1 |
| Behairy, M | 1 |
| Mady, G | 1 |
| Givvimani, S | 1 |
| Kundu, S | 1 |
| Pushpakumar, S | 1 |
| Doyle, V | 1 |
| Narayanan, N | 1 |
| Winchester, LJ | 1 |
| Veeranki, S | 1 |
| Metreveli, N | 1 |
| Tyagi, SC | 1 |
| Bartnicki, P | 1 |
| Kowalczyk, M | 1 |
| Franczyk-Skóra, B | 1 |
| Baj, Z | 1 |
| Rysz, J | 1 |
| Dückelmann, C | 2 |
| Mittermayer, F | 2 |
| Haider, DG | 2 |
| Altenberger, J | 2 |
| Wolzt, M | 2 |
| Lieb, W | 1 |
| Benndorf, RA | 1 |
| Benjamin, EJ | 1 |
| Sullivan, LM | 1 |
| Maas, R | 2 |
| Xanthakis, V | 1 |
| Aragam, J | 1 |
| Schulze, F | 1 |
| Vasan, RS | 1 |
| Dimitroulas, T | 1 |
| Giannakoulas, G | 1 |
| Papadopoulou, K | 1 |
| Karvounis, H | 1 |
| Dimitroula, H | 1 |
| Koliakos, G | 1 |
| Karamitsos, T | 1 |
| Parcharidou, D | 1 |
| Settas, L | 1 |
| Lehmann, HI | 1 |
| Goette, A | 1 |
| Martens-Lobenhoffer, J | 1 |
| Hammwöhner, M | 1 |
| Röhl, FW | 1 |
| Bukowska, A | 1 |
| Ghanem, A | 1 |
| Klein, HU | 1 |
| Bode-Böger, SM | 1 |
| Napora, M | 1 |
| Graczykowska, A | 1 |
| Próchniewska, K | 1 |
| Zdrojewski, Z | 1 |
| Całka, A | 1 |
| Górny, J | 1 |
| Stompór, T | 1 |
| Eichinger, J | 1 |
| Young, JM | 1 |
| Strey, CH | 1 |
| George, PM | 1 |
| Florkowski, CM | 1 |
| Sies, CW | 1 |
| Frampton, CM | 1 |
| Scott, RS | 1 |
| Zoccali, C | 1 |
| Mallamaci, F | 1 |
| Benedetto, FA | 1 |
| Tripepi, G | 1 |
| Malatino, LS | 1 |
| Cataliotti, A | 1 |
| Bellanuova, I | 1 |
| Böger, R | 1 |
1 trial available for n(g),n(g')-dimethyl-l-arginine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure.
Topics: Arginine; Atorvastatin; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heart Failur | 2008 |
14 other studies available for n(g),n(g')-dimethyl-l-arginine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Restoration of Adiponectin-Connexin43 Signaling Mitigates Myocardial Inflammation and Dysfunction in Diabetic Female Rats.
Topics: Adiponectin; Animals; Arginine; Connexin 43; Diabetes Mellitus, Experimental; Diabetes Mellitus, Typ | 2020 |
Elevated plasma levels of asymmetric dimethylarginine and the risk for arrhythmic death in ischemic and non-ischemic, dilated cardiomyopathy - A prospective, controlled long-term study.
Topics: Aged; Arginine; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Case-Control Studies; Female; Heart A | 2020 |
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
Topics: Amidohydrolases; Animals; Arginine; Atrial Natriuretic Factor; Disease Models, Animal; Fibrosis; Gen | 2017 |
Pre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function.
Topics: Animals; Arginine; Disease Models, Animal; Glutathione Peroxidase; Heart Diseases; Mice; Mice, Knock | 2018 |
Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
Topics: Adult; Arginine; Female; Glomerular Filtration Rate; Humans; Hypertension; Hypertrophy, Left Ventric | 2015 |
Hyperhomocysteinemia: a missing link to dysfunctional HDL via paraoxanase-1.
Topics: Amidohydrolases; Animals; Arginine; Aryldialkylphosphatase; Atherosclerosis; Blood Pressure; Connexi | 2015 |
Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease.
Topics: Aged; Arginine; Biomarkers; Case-Control Studies; Echocardiography, Doppler; Endothelium, Vascular; | 2016 |
Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure.
Topics: Aged; Arginine; Austria; Cohort Studies; Female; Heart Failure; Humans; Male; Middle Aged; Natriuret | 2008 |
Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample.
Topics: Aged; Arginine; Female; Heart Atria; Heart Ventricles; Humans; Linear Models; Male; Middle Aged; Mul | 2009 |
Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction.
Topics: Adult; Aged; Analysis of Variance; Arginine; Blood Flow Velocity; Echocardiography, Doppler; Endothe | 2010 |
Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Defibrillators, Implantable; Follow-Up Studies | 2011 |
Relationship between serum asymmetric dimethylarginine and left ventricular structure and function in patients with end‑stage renal disease treated with hemodialysis.
Topics: Arginine; Biomarkers; Echocardiography; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricu | 2012 |
Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure.
Topics: Aged; Arginine; Austria; Biomarkers; Disease-Free Survival; Female; Heart Failure; Humans; Male; Nat | 2007 |
Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
Topics: Adult; Aged; Arginine; Echocardiography; Endothelium, Vascular; Female; Humans; Hypertrophy, Left Ve | 2002 |